Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia

Stacey L. House, Craig Bolte, Ming Zhou, Thomas Doetschman, Raisa Klevitsky, Gilbert Newman, Jo El J. Schultz

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background-Preconditioning the heart before an ischemic insult has been shown to protect against contractile dysfunction, arrhythmias, and infarction. Pharmacological studies have suggested that fibroblast growth factor-2 (FGF2) is involved in cardioprotection. However, because of the number of FGFs expressed in the heart and the promiscuity of FGF ligand-receptor interactions, the specific role of FGF2 during ischemia-reperfusion injury remains unclear. Methods and Results-FGF2-deficient (Fgf2 knockout) mice and mice with a cardiac-specific overexpression of all 4 isoforms of human FGF2 (FGF2 transgenic [Tg]) were compared with wild-type mice to test whether endogenous FGF2 elicits cardioprotection. An ex vivo work-performing heart model of ischemia was developed in which murine hearts were subjected to 60 minutes of low-flow ischemia and 120 minutes of reperfusion. Preischemic contractile function was similar among the 3 groups. After ischemia-reperfusion, contractile function of Fgf2 knockout hearts recovered to 27% of its baseline value compared with a 63% recovery in wild-type hearts (P<0.05). In FGF2 Tg hearts, an 88% recovery of postischemic function occurred (P<0.05). Myocardial infarct size was also reduced in FGF2 Tg hearts compared with wild-type hearts (13% versus 30%, P<0.05). There was a 2-fold increase in FGF2 release from Tg hearts compared with wild-type hearts (P<0.05). No significant alterations in coronary flow or capillary density were detected in any of the groups, implying that the protective effect of FGF2 is not mediated by coronary perfusion changes. Conclusions-These results provide evidence that endogenous FGF2 plays a significant role in the cardioprotective effect against ischemia-reperfusion injury.

Original languageEnglish (US)
Pages (from-to)3140-3148
Number of pages9
JournalCirculation
Volume108
Issue number25
DOIs
StatePublished - Dec 23 2003

Fingerprint

Fibroblast Growth Factor 2
Ischemia
Myocardial Infarction
Reperfusion Injury
Reperfusion
Fibroblast Growth Factor Receptors
Recovery of Function
Knockout Mice
Infarction
Cardiac Arrhythmias
Protein Isoforms
Perfusion
Pharmacology
Ligands

Keywords

  • Growth substances
  • Ischemia
  • Myocardial infarction
  • Myocardial stunning

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia. / House, Stacey L.; Bolte, Craig; Zhou, Ming; Doetschman, Thomas; Klevitsky, Raisa; Newman, Gilbert; Schultz, Jo El J.

In: Circulation, Vol. 108, No. 25, 23.12.2003, p. 3140-3148.

Research output: Contribution to journalArticle

House, Stacey L. ; Bolte, Craig ; Zhou, Ming ; Doetschman, Thomas ; Klevitsky, Raisa ; Newman, Gilbert ; Schultz, Jo El J. / Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia. In: Circulation. 2003 ; Vol. 108, No. 25. pp. 3140-3148.
@article{9c2e3a981754414fae4aeb2938163bc1,
title = "Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia",
abstract = "Background-Preconditioning the heart before an ischemic insult has been shown to protect against contractile dysfunction, arrhythmias, and infarction. Pharmacological studies have suggested that fibroblast growth factor-2 (FGF2) is involved in cardioprotection. However, because of the number of FGFs expressed in the heart and the promiscuity of FGF ligand-receptor interactions, the specific role of FGF2 during ischemia-reperfusion injury remains unclear. Methods and Results-FGF2-deficient (Fgf2 knockout) mice and mice with a cardiac-specific overexpression of all 4 isoforms of human FGF2 (FGF2 transgenic [Tg]) were compared with wild-type mice to test whether endogenous FGF2 elicits cardioprotection. An ex vivo work-performing heart model of ischemia was developed in which murine hearts were subjected to 60 minutes of low-flow ischemia and 120 minutes of reperfusion. Preischemic contractile function was similar among the 3 groups. After ischemia-reperfusion, contractile function of Fgf2 knockout hearts recovered to 27{\%} of its baseline value compared with a 63{\%} recovery in wild-type hearts (P<0.05). In FGF2 Tg hearts, an 88{\%} recovery of postischemic function occurred (P<0.05). Myocardial infarct size was also reduced in FGF2 Tg hearts compared with wild-type hearts (13{\%} versus 30{\%}, P<0.05). There was a 2-fold increase in FGF2 release from Tg hearts compared with wild-type hearts (P<0.05). No significant alterations in coronary flow or capillary density were detected in any of the groups, implying that the protective effect of FGF2 is not mediated by coronary perfusion changes. Conclusions-These results provide evidence that endogenous FGF2 plays a significant role in the cardioprotective effect against ischemia-reperfusion injury.",
keywords = "Growth substances, Ischemia, Myocardial infarction, Myocardial stunning",
author = "House, {Stacey L.} and Craig Bolte and Ming Zhou and Thomas Doetschman and Raisa Klevitsky and Gilbert Newman and Schultz, {Jo El J.}",
year = "2003",
month = "12",
day = "23",
doi = "10.1161/01.CIR.0000105723.91637.1C",
language = "English (US)",
volume = "108",
pages = "3140--3148",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

TY - JOUR

T1 - Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia

AU - House, Stacey L.

AU - Bolte, Craig

AU - Zhou, Ming

AU - Doetschman, Thomas

AU - Klevitsky, Raisa

AU - Newman, Gilbert

AU - Schultz, Jo El J.

PY - 2003/12/23

Y1 - 2003/12/23

N2 - Background-Preconditioning the heart before an ischemic insult has been shown to protect against contractile dysfunction, arrhythmias, and infarction. Pharmacological studies have suggested that fibroblast growth factor-2 (FGF2) is involved in cardioprotection. However, because of the number of FGFs expressed in the heart and the promiscuity of FGF ligand-receptor interactions, the specific role of FGF2 during ischemia-reperfusion injury remains unclear. Methods and Results-FGF2-deficient (Fgf2 knockout) mice and mice with a cardiac-specific overexpression of all 4 isoforms of human FGF2 (FGF2 transgenic [Tg]) were compared with wild-type mice to test whether endogenous FGF2 elicits cardioprotection. An ex vivo work-performing heart model of ischemia was developed in which murine hearts were subjected to 60 minutes of low-flow ischemia and 120 minutes of reperfusion. Preischemic contractile function was similar among the 3 groups. After ischemia-reperfusion, contractile function of Fgf2 knockout hearts recovered to 27% of its baseline value compared with a 63% recovery in wild-type hearts (P<0.05). In FGF2 Tg hearts, an 88% recovery of postischemic function occurred (P<0.05). Myocardial infarct size was also reduced in FGF2 Tg hearts compared with wild-type hearts (13% versus 30%, P<0.05). There was a 2-fold increase in FGF2 release from Tg hearts compared with wild-type hearts (P<0.05). No significant alterations in coronary flow or capillary density were detected in any of the groups, implying that the protective effect of FGF2 is not mediated by coronary perfusion changes. Conclusions-These results provide evidence that endogenous FGF2 plays a significant role in the cardioprotective effect against ischemia-reperfusion injury.

AB - Background-Preconditioning the heart before an ischemic insult has been shown to protect against contractile dysfunction, arrhythmias, and infarction. Pharmacological studies have suggested that fibroblast growth factor-2 (FGF2) is involved in cardioprotection. However, because of the number of FGFs expressed in the heart and the promiscuity of FGF ligand-receptor interactions, the specific role of FGF2 during ischemia-reperfusion injury remains unclear. Methods and Results-FGF2-deficient (Fgf2 knockout) mice and mice with a cardiac-specific overexpression of all 4 isoforms of human FGF2 (FGF2 transgenic [Tg]) were compared with wild-type mice to test whether endogenous FGF2 elicits cardioprotection. An ex vivo work-performing heart model of ischemia was developed in which murine hearts were subjected to 60 minutes of low-flow ischemia and 120 minutes of reperfusion. Preischemic contractile function was similar among the 3 groups. After ischemia-reperfusion, contractile function of Fgf2 knockout hearts recovered to 27% of its baseline value compared with a 63% recovery in wild-type hearts (P<0.05). In FGF2 Tg hearts, an 88% recovery of postischemic function occurred (P<0.05). Myocardial infarct size was also reduced in FGF2 Tg hearts compared with wild-type hearts (13% versus 30%, P<0.05). There was a 2-fold increase in FGF2 release from Tg hearts compared with wild-type hearts (P<0.05). No significant alterations in coronary flow or capillary density were detected in any of the groups, implying that the protective effect of FGF2 is not mediated by coronary perfusion changes. Conclusions-These results provide evidence that endogenous FGF2 plays a significant role in the cardioprotective effect against ischemia-reperfusion injury.

KW - Growth substances

KW - Ischemia

KW - Myocardial infarction

KW - Myocardial stunning

UR - http://www.scopus.com/inward/record.url?scp=0346157995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346157995&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000105723.91637.1C

DO - 10.1161/01.CIR.0000105723.91637.1C

M3 - Article

C2 - 14656920

AN - SCOPUS:0346157995

VL - 108

SP - 3140

EP - 3148

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 25

ER -